Our Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. Our portfolio is made up of both patent-protected and off patent medicines.
We produce medicines to treat a broad range of acute and chronic diseases. These include respiratory disease, skin conditions and viral infections.
While our global pharmaceuticals portfolio covers seven areas – respiratory, immune-inflammation, infectious disease, cardiovascular, metabolic, dermatology and rare diseases – we are particularly known in Australia for our respiratory medicines.
Since the invention of our first asthma treatment in the 1960s, we have invested more in respiratory research than any other company worldwide. We remain committed to providing new treatment options for respiratory patients with three new medicines being approved in Australia in 2014 and more to come in the future.
Our pharmaceutical manufacturing plant in Melbourne’s outer-east is GSK’s largest manufacturing facility in the Southern Hemisphere. Our Boronia site is also our fourth-largest sterile facility housing a state-of-the-art Blow-Fill-Seal production line that runs 24 hours a day. Blow-Fill-Seal uses innovative technology for advanced antiseptic liquid medicines. Products manufactured this facility are exported to over 30 markets around the world.
Our HIV medicines are managed through ViiV Healthcare, a joint venture between GSK, Pfizer and Shionogi. ViiV Healthcare Australia has been involved in supporting research through investigator initiated clinical studies and operates its sales and marketing function from GSK’s Abbotsford office in Melbourne.
Read more about our pharmaceutical business here.